Treme targets cytotoxic T-lymphocyte antigen 4 (CTLA-4) and activates T cells by blocking the actions of CTLA-4, thereby enhancing the immune responses against cancer cells and inducing cancer cell death [4]. The gene discussed is CTLA4; the disease is cancer.